Welcome to EpilepsyU.com a social network dedicated to the epilepsy community

CBD for Epilepsy

Brain’s ‘natural marijuana’ may fight epilepsy, Malta researchers find

Could endocannabinoids be the key to reducing seizures? Boosting our own natural marijuana – known as endocannabinoids – is safer than using cannabis to block epileptic seizures, a group of University of Malta researchers have found.

Cannabidiol benefits and mechanisms shown in mouse study of Dravet syndrome

Treatment with cannabidiol reduces some major symptoms in mice with a genetic condition recapitulating Dravet syndrome, a devastating childhood brain disorder.   Cannabidiol is a non-intoxicating substance among the several active compounds derived from Cannabis plants. This molecule can also be produced synthetically.   The results of its use to treat Dravet syndrome are reported in the latest edition of the Proceedings of the National Academy of Sciences, PNAS.

Zynerba’s cannabis-based epilepsy gel fails in phase 2 trial

Zynerba Pharmaceuticals has reported that its cannabis-based epilepsy gel ZYN002 (cannabidiol [CBD] gel) has failed to meet the primary point in a phase 2 clinical trial. The trial dubbed as STAR 1 was held in 188 adult epilepsy patients with focal seizures across 14 sites in Australia and New Zealand. When compared to placebo, ZYN002 during the treatment period could not show a statistically significant decrease in focal seizures in comparison to the baseline period for either the high or low dose cohorts. STAR expands to Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy. The patients in the phase 2 trial were randomized to be treated during a 12-week period for every 12 hours with either 195mg of ZYN002 4.2% CBD gel, 97.5mg of ZYN002 4.2% CBD gel or placebo gel. The primary...

The DEA just gave a big boost to a cannabis-based seizure drug

We are often judged by the company we keep, even unfairly. For decades, that has been the fate of cannabidiol, a chemical compound that has the bad luck to occur naturally in marijuana, the world’s most controversial plant. Because cannabidiol is subject to the same tight legal restrictions on personal and scientific use as is marijuana, its potential medical benefits have been underappreciated — at least up until now.

Cannabis Product Reduces Epileptic Seizures in Lennox-Gastaut Syndrome, Study Shows

A medical cannabis product called RSHO-X dramatically reduced epileptic seizures in a Mexican study of Lennox-Gastaut syndrome, a severe form of childhood epilepsy that responds poorly to treatment. The study covered 39 patients who had daily seizures despite being treated with at least three anti-epileptic drugs. Seventeen percent of the participants had no seizures for at least four months, researchers said. Eighty-four percent had a 50 percent reduction in seizure activity. And more than half, 53 percent, saw their seizure activity drop by 75 percent.

CBD FOR EPILEPSY: To be available in Florida NEXT WEEK!

After 2 years of delays, appeals and uncertainty about availability, high-CBD, low-THC Medical Cannabis grown in Florida will finally be available next week to patients with prescriptions. Trulieve, located in Tallahassee, Florida, have announced that they have received the first formal authorization from the Florida DOH (Department of Health) to commence sales and dispensary of medicinal cannabis products. These CBD products are approved for persons with uncontrollable seizures and cancer and possibly other conditions. Children with Dravet syndrome and intractable and other hard-to-treat types of Epilepsy are expected to be greatly helped by the availability of high-CBD cannabis derived medicine. For more information check out Orlando Weekly, Miami Herald, or Orlando Sentinel and many oth...

CBD Treatment Gaining Legitimacy Through Research

Encouraging results from cannabidiol trial for treatment-resistant epilepsy Cannabidiol (CBD), a medical marijuana derivative, was effective in reducing seizure frequency and well-tolerated and safe for most children and young adults enrolled in a year-long study led by epilepsy specialists at NYU Langone Medical Center. These latest findings provide the first estimates of safety, tolerability and efficacy of prescription CBD in children and adults with severe, highly treatment-resistant epilepsy. Led by Orrin Devinsky, MD, professor of neurology, neurosurgery, and psychiatry and director of the Comprehensive Epilepsy Center at NYU Langone, the study is published in the December 23 issue of Lancet Neurology. While early findings have been released at medical meetings — including the ...

Advances in Epilepsy 2014, A Year in Review

2014 saw many changes in the understanding and treatments for epilepsy. As you all are well aware, Cannabis treatments became a major topic over the past few years, culminating in 2014 with many states passing compassionate care laws, like Florida’s Charlotte’s Web Bill (which won’t go into effect until 2015). Here is a roundup of some of the highlights from 2014. CBD FOR EPILEPSY While there is a growing body of evidence to support the treatment of seizures with cannabis, clinical trials are just beginning to shed some light on the effectiveness of CBD, one component of Cannabis that popular thought attributes to help seizures. EpilepsyU Conducted a CBD for Epilepsy Survey to gauge the public’s response to cannabis treatments and posted the results in easy to under...

NEW CBD for EPILEPSY SURVEY DATA RELEASED!

From May 20 to September 1 2014, Epilepsia conducted an online survey seeking opinions about the use of medical marijuana and cannabidiol (CBD) for people with epilepsy A MINORITY 48% of Specialists (Neurologists and Epileptologists) would recommend using medical marijuana in severe cases of epilepsy and an even smaller amount said that there was enough safety (34%) and efficacy (28%) data NEARLY ALL patients and general public (98%) would recommend medical marijuana in cases of severe epilepsy and feel there is enough safety (96%) and efficacy (95%) data A SUPER MAJORITY of general physicians, basic researchers, nurses, and allied health professions sided more with patients, saying that there were sufficient safety (70%) and efficacy (71%) data, and 83% would advise using marijuana in sev...

A New Candian Study Shows Dramatic Success With CBD Treatment for Epilepsy

PRESS RELEASE: VANCOUVER, British Columbia, Nov. 24, 2014 (GLOBE NEWSWIRE) — A new study from Orrin Devinsky, MD, of the New York University School of Medicine, suggests that Cannabidiol (CBD) may radically reduce seizures in patients with epilepsy. Dr. Devinsky administered cannabidiol to 23 patients with treatment-resistant epilepsy. Thirty-nine percent of the patients saw their seizure rates drop by more than 50%. Four patients (17%) had no seizures for the last month of treatment. Lexaria (CSE:LXX) (OTCQB:LXRP) has acquired 51% of PoViva Corp, an innovative health company developing Cannabidiol (CBD)-infused products. Lexaria may increase its ownership position to 75% at a later date. “Most CBD’s taste awful,” stated Lexaria CEO and Chairman Chris Bunka in an ex...

VIDEO: Charlotte’s Web for Epilepsy Consortium

The Epilepsy Association of Central Florida, EpilepsyU and The Realm of Caring Florida present “Charlotte’s Web: A Consortium for Understanding Florida’s Compassionate Care Law” at Concorde Career Institute, Orlando Florida. Filmed November 15, 2014 Featuring: Chuck Carmen, Director, Epilepsy Association of Central Florida Dr. Ngoc Minh Le, Epileptologist, Pediatric Neurology, P.A. Paige Figi, Founder, Realm of Caring and mother of Charlotte Figi Holly Moseley, Co-Fouder, Realm of Caring Florida Special thanks goes to Concorde Career Institute for hosting the event. PART 1 of 3 features Mr. Chuck Carmen giving an intro to epilepsy and the speakers and Dr. Le, Epileptologist with a presentation on CBD trials for Dravet and Lennox-Gasteaut Syndromes. PART 2 of 3 features Holley M...

Initial Data on ‘Pharma Grade’ Cannabidiol in Epilepsy

Initial data from an open-label study in treatment-resistant epilepsy of pharmaceutical-grade cannabidiol — the nonpsychoactive ingredient in marijuana that is believed to be responsible for its antiepileptic action — suggest that it reduces seizure rate by about 30%. The product, said to be 98% pure cannabidiol, in development under the brand name Epidiolex by GW Pharmaceuticals, which funded this study, was associated with a greater than 50% reduction in seizures in 39% of patients. Lead investigator, Orrin Devinsky, MD, New York University School of Medicine, said he thought the results were “encouraging.” “There appears to be potential for real benefit,” he told Medscape Medical News. A second study of patients using many different types of medical marijuana has...

  • 1
  • 2
  • 4

Lost Password

Register